

Working Groups

Annual Report of the Working Group of Cardiovascular Pharmacology and Pharmacotherapy: Final Report

1. Statement of the objectives of the Working Group

- ▣ To promote and organize research in the field of cardiovascular pharmacology and drug therapy
- ▣ To gather and exchange information regarding research and related activities within the Working Group
- ▣ To organize teaching workshops on topics related to cardiovascular pharmacology and drug therapy
- ▣ To hold regular meetings of the Working Group on specific topics
- ▣ To be involved in task forces of the European Society of Cardiology related to cardiovascular pharmacology
- ▣ To contribute to the organisation and preparation of the Annual Congress of the ESC
- ▣ To participate and support other scientific meetings and symposia

Following the restructuring of the Working Groups of the ESC, the Working Group on Cardiovascular Pharmacology and Drug Therapy is now in the Clinical Science Group in Cluster 1 together with the Working Groups on Rehabilitation and Exercise Physiology, Epidemiology and Prevention, and Cardiovascular Nursing.

2. Number of sessions organized at the ESC Annual Congress

- 2.1. Together with the Working Groups on Cellular Biology of the Heart, Myocardial Function and Cardiac Cellular Electrophysiology as well as Microcirculation and Thrombosis and Platelets: Nuclear-hormone receptor-directed therapy - an emerging concept in the treatment of cardiovascular disease
- 2.2. Together with the Working Group on Thrombosis and Platelets: Risk/benefit of combining antithrombotic treatments
- 2.3. Together with the European Atherosclerosis Society and the International Society of Cardiovascular Pharmacotherapy: The lipid-related risk and lipid-lowering treatment
- 2.4. Together with the Working Group on Epidemiology and Prevention: Cardiovascular risk in European and United States cohort studies: a comparative review
- 2.5 Together with the Working Group on Cardiovascular Nursing: The older cardiac patient: what can and what should we do?

3. Activities run outside the ESC Annual Congress:

- 3.1. In-house ETP course at the European Heart House, November 25-27, 1999, Analysis of clinical trials from statistics to clinical practice
- 3.2. Annual Meeting of the Working Group, April 8, 2000, Paris, New trends in cardiovascular pharmacology and therapeutics

4. Membership of Working Group:

Presently our Working Group has about 100 members. According to the suggestions made by the Science Council of the ESC, application for membership in our Working Group should be made in writing to the Chairman of the Working Group accompanied by a written statement of two members of the Working Group reflecting the applicant's qualifications, plus a copy of the applicant's CV including a list of the three most recent relevant papers.

5. Registries, survey

Together with the Working Group on Epidemiology, we presently are performing a survey on angina treatment patterns in Europe (characteristics of a contemporary population with angina pectoris in Europe, W. Klein, J.R. Hampton)

6. Study groups

- ▣ Heart failure in clinical practice: Use and misuse of polypharmacy (E. Ambrosioni)
- ▣ Treatment of cardiovascular disorders in patients with multimorbidity (F. Follath)
- ▣ Stroke prevention in patients with cardiovascular disease (P. Lechat)

Task forces

The Working Group on Cardiovascular Pharmacology and Pharmacotherapy is involved in on-going task forces on bacterial endocarditis, joint study group on treatment of refractory angina, update of task force on congestive heart failure and the second joint task force on prevention of coronary heart disease in clinical practice.